NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 05/15/2026 12:19 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Telesis Bio Stock (NASDAQ:TBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Telesis Bio alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range$0.00▼$0.0652-Week Range$0.00▼$0.30Volume556 shsAverage Volume493 shsMarket Capitalization$1.80 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telesis Bio, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications. The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants. These agents are being evaluated both as monotherapies in solid tumors and in combination with checkpoint inhibitors, with the goal of converting immunologically “cold” tumors into “hot” ones that are more likely to respond to treatment. In parallel, Telesis Bio is exploring the use of its PRR agonists as adjuvants in therapeutic and prophylactic vaccines, aiming to improve antigen-specific immune activation. Founded in 2015 and headquartered in South San Francisco, California, Telesis Bio collaborates with leading academic institutions and biotechnology partners to accelerate its research and development efforts. The company is led by an experienced management team with expertise in immunology, molecular biology, and clinical development. Telesis Bio continues to expand its platform through strategic partnerships and preclinical studies, with the objective of delivering next-generation immunotherapies to patients in the United States and globally.AI Generated. May Contain Errors. Read More Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBIO Stock News HeadlinesTelesis Bio, Inc. Common Stock (TBIO)May 14, 2026 | nasdaq.comTelesis Bio Inc.April 17, 2026 | barrons.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Telesis Bio Inc (TBIO) Stock Forums - Investing.comJune 29, 2025 | investing.comTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisMay 28, 2025 | finance.yahoo.comTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comTelesis Bio Shares Double After News of Beckman Coulter Life Sciences CollaborationSeptember 27, 2024 | marketwatch.comSee More Headlines TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $0.05 at the beginning of 2026. Since then, TBIO shares have decreased by 98.0% and is now trading at $0.0010. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) issued its quarterly earnings data on Monday, November, 8th. The company reported ($6.12) EPS for the quarter, missing the consensus estimate of ($5.04) by $1.08. The firm earned $2.79 million during the quarter, compared to the consensus estimate of $2.93 million. When did Telesis Bio's stock split? Telesis Bio shares reverse split on the morning of Thursday, May 9th 2024.The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPENG (XPEV). Company Calendar Last Earnings11/08/2021Today5/18/2026Next Earnings (Estimated)5/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees200Year Founded2013Profitability EPS (Trailing Twelve Months)($20.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.72 million Net Margins-336.59% Pretax Margin-334.81% Return on EquityN/A Return on Assets-61.89% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.06 Sales & Book Value Annual Sales$225.09 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book0.01Miscellaneous Outstanding Shares1,802,000Free Float1,360,000Market Cap$1.80 thousand OptionableNo Data Beta2.29 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TBIO) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
